

Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 32. (Canceled)

33. (Previously Presented) An anhydrous pharmaceutical composition combining at least one active ingredient and a silicone agent comprising at least one organopolysiloxane elastomer and a thickening agent different from the silicone agent, said active ingredient being in a solubilized form in said composition.

34. (Previously Presented) An anhydrous pharmaceutical composition combining at least one active ingredient and a silicone agent, said active ingredient being in a solubilized form in said composition, said silicone agent comprising at least one organopolysiloxane elastomer prepared by crosslinking reaction between :

- polysiloxanes (A) containing $\equiv\text{Si-H}$ groups represented by the compounds of formula $\text{R}^{14}_3\text{SiO}(\text{R}^{15}_2\text{SiO})_a(\text{R}^{16}\text{HSiO})_b\text{SiR}^{14}_3$ here denoted as type A^1 , and compounds of formula $\text{HR}^{14}_2\text{SiO}(\text{R}^{15}_2\text{SiO})_c\text{SiR}^{14}_2\text{H}$ or of formula $\text{HR}^{14}_2\text{SiO}(\text{R}^{15}_2\text{SiO})_a(\text{R}^{16}\text{HSiO})_b\text{SiR}^{14}_2\text{H}$ here denoted as type A^2 , in these formulae, R^{14} , R^{15} and R^{16} are alkyl groups having from 1 to 6 carbon atoms, a is an integer ranging from 0 to 250, b is in integer ranging from 1 to 250, and c is an integer ranging from 0 to 250, the molar ratio of the compounds A^2 : A^1 being from 0 to 20,
- an alpha, omega-diene (B) which is a compound of formula $\text{CH}_2=\text{CH}(\text{CH}_2)_d\text{CH}=\text{CH}_2$ in which d is an integer ranging from 1 to 20, in the presence of a catalyst, and
- a low molecular weight linear or cyclic polysiloxane (C), being a cyclic volatile methylsiloxane chosen among hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane.

35. (Previously Presented) The composition as claimed in claim 33, wherein it is intended for topical application.

36. (Previously Presented) The composition as claimed in claim 33, wherein it is in the form of a gel.

37. (Previously Presented) The composition as claimed in claim 33, wherein it has a water content of less than or equal to 5%, in particular less than or equal to 3% by weight relative to the total weight of the composition, and in particular equal to zero.

38. (Previously Presented) The composition as claimed in claim 33, wherein said active ingredient is solubilized using at least one solvent agent.

39. (Previously Presented) The composition as claimed in claim 33, wherein it comprises at least one silicone agent, a hydrocarbon-based compound, in particular of pasty or solid type, an active ingredient in a solubilized form, and an alcohol-type solvent.

40. (Previously Presented) The composition as claimed in claim 33, characterized in that said active ingredient is chosen from vitamin D and its derivatives.

41. (Previously Presented) The composition as claimed in claim 33, wherein said active ingredient is present at a content of from 0.0001 to 20%, in particular from 0.01 to 15%, and more particularly from 0.025 to 5% by weight relative to the total weight of the composition.

42. (Previously Presented) The composition as claimed in claim 38, wherein said solvent agent is chosen from alcohols such as ethanol.

43. (Previously Presented) The composition as claimed in claim 38, wherein the content of solvent agent is from 1% to 50%, in particular from 2% to 40%, and more particularly from 5% to 10% by weight relative to the total weight of the composition.

44. (Previously Presented) The composition as claimed in claim 33, wherein the

content of elastomer is from 1% to 20%, and in particular from 4% to 12% by weight relative to the total weight of the composition.

45. (Previously Presented) The composition as claimed in claim 33, wherein the elastomer is formulated in at least one volatile silicone oil.

46. (Previously Presented) The composition as claimed in claim 45, wherein said volatile silicone oil is chosen from linear or cyclic polyorganosiloxane oils having from 2 to 10 silicon atoms.

47. (Previously Presented) The composition as claimed in claim 33, wherein the content of silicone agent is from 20% to 80%, and in particular from 30% to 70% by weight relative to the total weight of the composition.

48. (Previously Presented) The composition as claimed in claim 33, wherein said thickening agent is chosen from solid or pasty hydrocarbon-based compounds.

49. (Previously Presented) The composition as claimed in claim 39, wherein the hydrocarbon-based compound is chosen from hydrocarbon-based waxes of animal, plant, mineral or synthetic origin, and mixtures thereof.

50. (Currently Amended) The composition as claimed in claim 49, wherein said hydrocarbon-based wax is chosen from glyceryl esters and esters of saturated, unsaturated and in particular polyunsaturated fatty acids having from 10 to 24 carbon atoms.

51. (Previously Presented) The composition as claimed in claim 50, wherein said wax is chosen from glyceryl behenate and glyceryl dipalmitostearate, and mixtures thereof.

52. (Previously Presented) The composition as claimed in claim 39, wherein said hydrocarbon-based compound is present at a content ranging from 2% to 80%, and in particular from 4% to 30% by weight relative to the total weight of the composition.

53. (Previously Presented) The composition as claimed in claim 39, wherein said

composition has occlusive properties.

54. (Previously Presented) The composition as claimed in claim 33, wherein it also comprises at least one agent for diluting the silicone agent.

55. (Previously Presented) The composition as claimed in claim 54, wherein said diluting agent is chosen from linear or cyclic volatile silicone oils.

56. (Previously Presented) The composition as claimed in claim 33, wherein it also comprises at least one agent for promoting the penetration of the active ingredient into the skin.

57. (Previously Presented) The composition as claimed in claim 56, wherein said agent for promoting the penetration of the active ingredient into the skin is chosen from glycols, glycol ethers, fatty acids, fatty acid esters, glycol esters, glycerides, azones, polysorbates, alkanols, dimethyl sulfoxide, and mixtures thereof.

58. (Previously Presented) The composition as claimed in claim 56, wherein said agent for promoting the penetration of the active ingredient into the skin is present at a content ranging from 2% to 30%, and in particular from 4% to 25% by weight relative to the total weight of the composition.

59. (Previously Presented) The composition as claimed in claim 33, wherein it also comprises at least one pharmaceutically acceptable additive.

60. (Previously Presented) A method for preparation of an anhydrous pharmaceutical composition comprising at least one active ingredient in a solubilized form and with prolonged stability, comprising combining said active ingredient, at least one organopolysiloxane elastomer and a thickening agent different from said silicone agent.

61. (Previously Presented) A method for the preparation of an anhydrous pharmaceutical composition comprising at least one active ingredient in a solubilized form

and with prolonged stability comprising combining said active ingredient and a silicone agent as defined in claim 34.

62. (Previously Presented) The method as claimed in claim 60 wherein said silicon agent is the content of elastomer is from 1% to 20%, and in particular from 4% to 12% by weight relative to the total weight of the composition.

63. (Previously Presented) The use as claimed in claim 60 wherein said composition is an anhydrous pharmaceutical composition combining at least one active ingredient and a silicone agent comprising at least one organopolysiloxane elastomer and a thickening agent different from the silicone agent, said active ingredient being in a solubilized form in said composition.

64. (Previously Presented) A method for the treatment of psoriasis, comprising administering to a subject requiring treatment of psoriasis a composition as claimed in claim 33.